Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Marcador preoperatorio para diagnóstico y diferenciación de carcinoma renal

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20180309001
Publicado:
23/03/2018
Caducidad:
24/03/2019
Resumen:
Una universidad alemana ha desarrollado un marcador de diagnóstico y diferenciación no invasivo del carcinoma renal benigno y maligno. La diferenciación inequívoca mejora la planificación del tratamiento adecuado. La universidad ha identificado la vimentina 3, que representa un nuevo enfoque para diferenciar un oncocitoma benigno de carcinomas malignos. La detección de los marcadores en la orina permite a los urólogos y oncólogos realizar por primera vez un diagnóstico preoperatorio con una prueba no invasiva para llevar a cabo un diagnóstico adecuado y planificar el seguimiento. La universidad busca socios con el fin de establecer acuerdos de licencia para desarrollar el producto final a partir del prototipo.

Details

Tittle:
Preoperative marker for diagnosis and differentiation of renal carcinoma.
Summary:
A German university has developed a marker for non-invasive diagnosis and differentiation of benign and malignant renal carcinoma. An unequivocal differentiation will improve the planning of the adequate treatment. The university offers a license agreement.
Description:
Kidney cancer is classified as malignant tumors originating from different renal cells with several subtypes. The cells of these subtypes can mimic a benign kidney tumor, called oncocytomas. The unequivocal differentiation is essential for planning the adequate operative procedure and the patient follow-up monitoring (which is not necessary for oncocytomas). To date, it is not possible to reliably differentiate between malignant subtypes and benign kidney tumors by means of the available antibody panel and imaging methods.

A German university found a splice isoform of Vimentin, namely Vimentin3 (Vim3), as an indicator of benign oncocytomas. Renal cell carcinomas (RCCs) are negative for Vim3. They also discovered a truncated variant of the protein MAPK p38, namely Mxi-2, which indicates RCC, including all subtypes. Oncocytomas, however, is negative for Mxi-2. Both markers are detectable by means of monoclonal antibodies directed against Vim3 and Mxi-2 in body fluids, such as urine, as well as in tissue.

Detection of both markers in urine makes it possible for the first time to provide urologists and oncologists with a non-invasive test for a pre-operative diagnosis so as to appropriately treat the patient and plan the follow-up.

The marker is also usable for routine medical check-ups (for persons aged 55 and above).

The university offers a license agreement to companies from the diagnostic industry. The partner should cooperate to further develop the prototype to a final product.
Advantages and Innovations:
The identified vimentim3 represents a novel approach to differentiate a benign oncocytoma from malignant carcinomas. Apart from the fact that this procedure will improve the diagnosis it will also optimize the treatment of the patients.
Stage of Development:
Available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A European and US-American patent has been filed.

Partner sought

Type and Role of Partner Sought:
The university offers a license agreement

Potential licensees come from the diagnostic industry. Especially those companies that offer immunohistochemical analyses and investigations in body fluids (by means of antibody detection) are addressed, specifically urine diagnostics.

The cooperation would include the further development to a ready to use product. This involves the relevant studies. Meanwhile the prototype is under development (test strip and ELISA test).

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis